โ
๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ
โข Revenue: โฌ1.289B (-15.1% YoY)
โข IFRS EPS: โฌ0.73 vs. -โฌ0.12 YoY
โข Adjusted EPS: โฌ1.76 vs. โฌ3.11 YoY
โข IFRS Net Profit: โฌ184.5M vs. โฌ28.7M loss YoY
โข Adjusted Net Profit: โฌ440.9M vs. โฌ752.5M YoY
โข R&D Expenses: โฌ748.1M vs. โฌ564.8M YoY
โข Adjusted R&D Expenses: โฌ578.5M vs. โฌ479.4M YoY
โข SG&A Expenses: โฌ178.5M vs. โฌ148.5M YoY
โ
๐ฏ ๐๐ฎ๐ข๐๐๐ง๐๐ (๐ ๐๐๐, ๐๐๐ข๐ฌ๐๐)
โข Revenue: โฌ1.7Bโโฌ1.9B (prior โฌ1.6Bโโฌ1.9B)
โข Adjusted R&D Expenses: โฌ2.0Bโโฌ2.3B, reaffirmed
โข Adjusted SG&A Expenses: โฌ700Mโโฌ800M, reaffirmed
โ
๐ ๐๐๐ฒ ๐๐๐ค๐๐๐ฐ๐๐ฒ๐ฌ
โข Pumitamig plus elfetabart drozuntecan delivered first global clinical combination data for a PD-(L)1xVEGF bispecific with an investigational ADC in lung cancer
โข Advanced Phase 3 trial plans combining pumitamig with Gilead's Trodelvy in triple-negative breast cancer, pending regulatory approval
โข Gotistobart nearly doubled median overall survival versus chemotherapy in previously treated squamous non-small cell lung cancer
โข Launched updated 2026/27 COVID-19 vaccines with Pfizer across multiple markets
โข Roche/Genentech to generally assume R&D costs for an existing collaboration program starting January 2027, with BioNTech retaining potential royalties
โข YTD Revenue: โฌ1.513B vs. โฌ1.963B YoY
โข YTD IFRS Net Loss: โฌ1.168B vs. โฌ831.1M YoY
โข Cash, Equivalents & Securities: โฌ16.16B
โข Repurchased $463.3M in ADSs under its $1B buyback program through September
โข Continued investment in late-stage oncology and ADC programs while prioritizing pipeline assets
โ
๐ฌ ๐๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐๐จ๐ฆ๐ฆ๐๐ง๐ญ๐๐ซ๐ฒ
โWith a growing pipeline, key registrational trials, strategic partnerships, and financial strength, BioNTech is well positioned for its next phase of growth as we advance toward becoming a diversified, multi-product company by 2030.โ โ CEO Ugur Sahin